Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opdivo Success In Early Melanoma Paves Way For Other Tumor Types

Executive Summary

Study finds that Bristol-Myers Squibb's PD-1 inhibitor Opdivo beats the company's CTLA-4 inhibitor Yervoy in Stage III/C or Stage IV melanoma, spurring hopes for ongoing studies in other tumor types.


Related Content

Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2
Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
Opdivo Gets A Melanoma Rejection, But Also An Expansion


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts